A $9 billion valuation built on a device that didn’t work — and a revenue claim that was off by three orders of magnitude.
Theranos was a health technology company founded in 2003 in Palo Alto, California, that falsely claimed to perform rapid, accurate blood tests using minimal blood volume via proprietary devices; investigations revealed it relied on conventional machines, produced inaccurate results, voided two years of Edison data, and misrepresented its capabilities to investors, partners, and regulators.
Theranos was founded in 2003 by Elizabeth Holmes, who pitched a radical reimagining of blood testing using fingerprick samples.
2:10
The Device That Wasn’t Used
Theranos claimed to run tests on its proprietary Edison device — but used third-party machines for most testing.
4:05
The Data That Was Erased
The Edison device produced inaccurate results — so Theranos voided two years of its own data.
5:33
The Funding Built on Lies
Theranos raised $700 million by lying — about accuracy, military use, and revenue.
6:44
The Breakthrough That Wasn’t
Theranos was publicly presented as a breakthrough — but its breakthrough existed only in press releases and boardrooms.
Worth your time?
Yes. Study the whole thing.
1.5/ 5
What works
marketing
fundraising
legal intimidation
What does not
works
delivers
validates
scales
Study it if
investors
regulators
patients
Skip it if
clinicians
scientists
consumers
The written brief1 min read
What the company or idea is
Theranos was a health technology company founded in 2003 in Palo Alto, California, that falsely claimed to perform rapid, accurate blood tests using minimal blood volume via proprietary devices.
How it actually makes money
Theranos made no meaningful revenue: it claimed a $100-million revenue stream in 2014 but actually made only $100,000.
What works
Nothing worked at scale. Its core device failed. Its clinical validation failed. Its commercial partnerships collapsed when tested. Its financial claims were fabricated.
What does not
Its Edison device did not work. It gave inaccurate results. Theranos voided two years of its data. It did not use its own devices for most tests — it relied on commercially available machines from other manufacturers.
What to take from it
A company’s valuation is not evidence of technical validity. When the gap between marketing claims and operational reality is wide — and enforced by secrecy and litigation — the business model is fraud, not innovation.
Is it worth your time
Yes — as a case study in how false claims about technical capability, when backed by aggressive legal intimidation and media manipulation, can attract $700 million in investment without delivering a functional product.